Stocktoria
Walvax Biotechnology Co., Ltd. 300142.SZ
CN · XSHE · XSHE · stock · Healthcare · website
Walvax Biotechnology Co., Ltd. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | CN¥2.4B | CN¥2.8B | CN¥4.1B | CN¥5.1B |
| Gross profit | CN¥1.8B | CN¥2.2B | CN¥3.5B | CN¥4.5B |
| R&D expense | CN¥291.9M | CN¥596.5M | CN¥776.4M | CN¥932.9M |
| SG&A expense | CN¥1.0B | CN¥1.1B | CN¥1.6B | CN¥2.1B |
| Operating income | CN¥340.9M | CN¥291.8M | CN¥1.0B | CN¥1.3B |
| Interest expense | -CN¥2.2M | CN¥8.4M | CN¥5.9M | CN¥7.1M |
| Income tax | CN¥41.0M | CN¥10.1M | CN¥87.7M | CN¥132.2M |
| Net income | CN¥177.7M | CN¥142.2M | CN¥419.4M | CN¥728.7M |
| EPS (diluted) | CN¥0.11 | CN¥0.09 | CN¥0.26 | CN¥0.45 |
| Operating cash flow | CN¥490.9M | CN¥1.0B | CN¥1.1B | CN¥1.2B |
| Free cash flow | -CN¥18.6M | CN¥486.5M | CN¥188.3M | CN¥110.3M |
| Cash & equivalents | CN¥1.4B | CN¥3.8B | CN¥4.4B | CN¥3.9B |
| Inventory | CN¥574.2M | CN¥752.6M | CN¥1.0B | CN¥995.8M |
| Goodwill | CN¥33.7M | CN¥33.7M | CN¥33.7M | CN¥33.7M |
| Total assets | CN¥12.1B | CN¥14.7B | CN¥15.6B | CN¥15.3B |
| Total debt | CN¥388.6M | CN¥491.9M | CN¥806.4M | CN¥462.5M |
| Total liabilities | CN¥2.5B | CN¥3.2B | CN¥4.2B | CN¥4.3B |
| Shareholders' equity | CN¥8.6B | CN¥9.4B | CN¥9.3B | CN¥9.1B |
Growth · year-over-year · Revenue CAGR -22%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | -14.3% | -31.4% | -19.1% | — |
| Net income growth | +25.0% | -66.1% | -42.4% | — |
| EPS growth | +25.0% | -66.1% | -42.3% | — |
| Free cash flow growth | -103.8% | +158.4% | +70.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · CN · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.